
|Videos|June 2, 2014
Are Expensive New Hepatitis C Drugs Worth the High Cost?
Author(s)Davy James, Associate Editor
Stephen Vogt, PharmD, Chief Executive Officer and President of BioPlus Specialty Pharmacy, discusses the ongoing debate surrounding the high price of Hepatitis C treatments versus the efficacy of the drug.
Advertisement
Stephen Vogt, PharmD, Chief Executive Officer and President of BioPlus Specialty Pharmacy, discusses the ongoing debate surrounding the high price of Hepatitis C treatments versus the efficacy of the drug.
This video was shot at the Armada Health Care 2014 Specialty Pharmacy Summit and Expo in Las Vegas, Nevada.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
The Biosimilar Conversation Nobody Is Having at the Pharmacy Counter: Why Adoption Is Still Struggling and What We Can Do About It
2
Medicare Is Finally Covering GLP-1s for Weight Loss: What the Bridge Program Means for Your Practice
3
FDA Narrows Compounding Rules for GLP-1s: How Pharmacists Should Respond
4
Closing the Gaps in Men’s Health Through MTM and Community Engagement
5


















































































































